MedTrace Logo

TDXD in Metastatic HER2-Positive Breast Cancer

NCT07778407 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-08-21

No results posted yet for this study

Summary

A single-center observational study (retrospective + prospective) evaluating the real-world efficacy and toxicity profile of Trastuzumab Deruxtecan (T-DXd) in adult female patients with HER2-positive metastatic breast cancer treated at KSAMC, Madinah, Saudi Arabia

Conditions

  • Breast Advanced Malignancies

Interventions

DRUG

Trastuzumab deruxtecan (T-DXd)

Dose 5.4 mg/kg IV Frequency Every 3 weeks (Q3W) Route Intravenous infusion Line of Therapy 2nd line (post-adjuvant progression) or 3rd line and beyond (de novo metastatic)

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2026-02-10
Completion
2026-05-01

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07778407 on ClinicalTrials.gov